Latest Ibritumomab tiuxetan Stories
- Spectrum receives a 19.99% stake (pre-transaction) in CASI, a NASDAQ-listed, oncology-focused Company with expertise and focus on markets in China and a $1.5 million promissory note HENDERSON,
In a Breaking News Exclusive, Jamie Reno writes how GSK's spokesperson informed him that Bexxar, a lifesaving cancer drug is being discontinued in February 2014.
A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.
A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients’ lymphoma can be eradicated as they prepare for bone marrow transplant.
Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system.
A University of Rochester Medical Center study challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis.